MR imaging in the evaluation of isolated limb perfusion: A prospective study of 18 cases

Skeletal Radiology

Volumn 33, Issue 3, 2004, Pages 150-156

  Vanel, Daniel ^a   Bonvalot, Sylvie ^a   Guinebretière, Jean Marc ^b   Petrow, Peter ^a   Dromain, Clarisse ^a   Caillet, Hubert ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

Chemotherapy; Isolated limb perfusion; Magnetic resonance (MR); Soft tissues, neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LEG BLOOD FLOW; LIMB AMPUTATION; LIMB PERFUSION; LUNG METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; TUMOR CELL; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MELPHALAN; MIDDLE AGED; PROSPECTIVE STUDIES; SALVAGE THERAPY; SARCOMA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1542375466     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-003-0726-x     Document Type: Article

References (14)

1. Lejeune FJ, Kroon BB, Di Filippo F, et al. Isolated limb perfusion: the European experience. Surg Oncol Clin North Am 2001; 10:821-832.
2. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224:756-764.
3. Eggermont AM, Ten Hagen TL. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 2001; 3:359-367.
4. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653-2665.
5. Lev-Chelouche D, Abu-Abeid S, Kollander Y, et al. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan. J Surg Oncol 1999; 70:185-189.
6. Bickels J, Manusama ER, Gutman M, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. Eur J Surg Oncol 1999; 25:509-514.
7. De Schepper AM, Ramon FA, Degryse HR. Statistical analysis of MRI parameters predicting malignancy in 141 soft tissue masses. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1992; 156:587-591.
8. Vanel D, Shapeero LG, De Baere T, et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumors: results of 511 examinations. Radiology 1994; 190:263-268.
9. Shapeero LG, Vanel D, Verstraete KL, Bloem JL. Fast magnetic resonance imaging with contrast for soft tissue sarcoma viability. Clin Orthop 2002; 397:212-227.
10. Erlemann R. Dynamic, gadolinium-enhanced MR imaging to monitor tumor response to chemotherapy. Radiology 1993; 186:904-905.
11. De Baere T, Vanel D, Shapeero LG, Charpentier A, Terrier P, Di Paola M. Osteosarcoma after chemotherapy: evaluation with contrast material-enhanced subtraction MR imaging. Radiology 1992; 185:587-592.
12. Van Der Woude HJ, Bloem JL, Holscher HC, et al. Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging. Skeletal Radiol 1994; 23:493-500.
13. Verstraete KL, De Deene Y, Roels H, Dierick A, Uyttendaele D, Kunnen M. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging parametric "first-pass" images depict tissue vascularization and perfusion. Radiology 1994; 192:835-843.
14. Van Ginkel RJ, Hoekstra HJ, Pruim J, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 1996; 37:984-990.